The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice

Res Vet Sci. 2007 Apr;82(2):239-41. doi: 10.1016/j.rvsc.2006.06.006. Epub 2006 Aug 17.


Canine mast cell tumors (MCTs) are the most common cutaneous tumors in the dog. They have a wide range of behaviour, which can make these tumors challenging to treat. Recently, mutations in c-kit proto-oncogene have been identified in several canine MCTs. Imatinib is the first member of a new class of agents that act by inhibiting particular tyrosin kinase enzymes, including KIT which is a product of the c-kit. In this study the efficacy of imatinib to reduce or abolish canine MCT [CMC-1] using xenografted MCT in severe combined immunodeficient [SCID] mice was evaluated. Imatinib was administered at doses of 200mg/kg and 100mg/kg once a day for one week. The antitumor responses in SCID mice with CMC-1 xenografts following treatment with imatinib were observed. Significant tumor regression occurred with 100mg/kg on days 7, 10, 14 and 21, and 200mg/kg on all days. Our results indicate that imatinib is effective against canine mast cell tumor in mouse xenograft models. Canine MCTs might be a potential target for imatinib therapy.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Benzamides
  • Dog Diseases / drug therapy*
  • Dog Diseases / pathology
  • Dogs
  • Imatinib Mesylate
  • Mast-Cell Sarcoma / drug therapy*
  • Mast-Cell Sarcoma / pathology
  • Mast-Cell Sarcoma / veterinary*
  • Mice
  • Mice, SCID
  • Piperazines / pharmacology*
  • Pyrimidines / pharmacology*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / veterinary*
  • Specific Pathogen-Free Organisms
  • Statistics, Nonparametric
  • Xenograft Model Antitumor Assays


  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate